Epicleriti and cleriti: clinical feature and treatment reult

PURPOE: To evaluate the clinical experience with epicleriti and cleriti at a tertiary care eye center. METHOD: Retropective chart review. REULT: One hundred thirty-four patient with cleral inflammation were een over a 12-year period. Thirty-even patient had epicleriti, and 97 patient had cleriti. Ocular complication occurred in only 13.5% of patient with epicleriti but in 58.8% of patient with cleriti (P < .0001). No patient with epicleriti had a decreae in viual acuity, wherea 15.9% of patient with cleriti did. Only 16.7% of patient with epicleriti required more than topical corticoteroid for treatment, and thee patient required oral nonteroidal anti-inflammatory drug. Converely, 30.4% of patient with cleriti required nonteroidal anti-inflammatory drug, 31.9% oral prednione, and 26.1% ytemic immunouppreive drug (P < .0001). Necrotizing cleriti and poterior cleriti more often were aociated with ocular complication, occurring in 91.7% and 85.7%, repectively, than were diffue anterior cleriti and nodular anterior cleriti (P = .020). Patient with necrotizing cleriti and poterior cleriti were more likely to be treated with oral corticoteroid or immunouppreive drug (90% and 100%, repectively) than were patient with diffue anterior cleriti and nodular anterior cleriti (56.4% and 21.4%, repectively, P = .002). CONCLUION: cleriti i a evere ocular inflammation, often aociated with ocular complication, and nearly alway treated with ytemic medication. Nearly 60% of thee patient will need oral corticoteroid or immunouppreive drug to control the dieae.